Literature DB >> 17072613

Defining co-related parameters between 'metabolic' flare and 'clinical', 'biochemical', and 'osteoblastic' flare and establishing guidelines for assessing response to treatment in cancer.

Sandip Basu, Abass Alavi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17072613     DOI： 10.1007/s00259-006-0264-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  19 in total

1.  Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer.

Authors:  M Koizumi; S Matsumoto; S Takahashi; T Yamashita; E Ogata
Journal:  Clin Nucl Med       Date:  1999-01       Impact factor: 7.794

2.  Fluorodeoxyglucose positron emission tomography scan of prostate cancer bone metastases with flare reaction after endocrine therapy.

Authors:  N Shimizu; H Masuda; H Yamanaka; N Oriuchi; T Inoue; K Endo
Journal:  J Urol       Date:  1999-02       Impact factor: 7.450

3.  Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.

Authors:  F Dehdashti; F L Flanagan; J E Mortimer; J A Katzenellenbogen; M J Welch; B A Siegel
Journal:  Eur J Nucl Med       Date:  1999-01

4.  Correlation between bone scans and serum levels of osteocalcin, prostate-specific antigen, and prostatic acid phosphatase in monitoring patients with disseminated cancer of the prostate.

Authors:  M Tarle; K Kovaćić; A Strelkov-Alfirević
Journal:  Prostate       Date:  1989       Impact factor: 4.104

Review 5.  Use of PET for monitoring cancer therapy and for predicting outcome.

Authors:  Wolfgang A Weber
Journal:  J Nucl Med       Date:  2005-06       Impact factor: 10.057

6.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

Review 7.  Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.

Authors:  I M Thompson; E J Zeidman; F R Rodriguez
Journal:  J Urol       Date:  1990-12       Impact factor: 7.450

8.  Metabolic flare: indicator of hormone responsiveness in advanced breast cancer.

Authors:  J E Mortimer; F Dehdashti; B A Siegel; K Trinkaus; J A Katzenellenbogen; M J Welch
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

9.  Bone scan flare predicts successful systemic therapy for bone metastases.

Authors:  R E Coleman; G Mashiter; K B Whitaker; D W Moss; R D Rubens; I Fogelman
Journal:  J Nucl Med       Date:  1988-08       Impact factor: 10.057

Review 10.  PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus.

Authors:  Lale Kostakoglu; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057
View more
  6 in total

1.  Critical considerations on the combined use of ¹⁸F-FDG and ¹⁸F-fluoride for PET assessment of metastatic bone disease.

Authors:  Gang Cheng; Thomas C Kwee; Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-22       Impact factor: 9.236

2.  Quantitative contrast-enhanced CT attenuation evaluation of osseous metastases following chemotherapy.

Authors:  Connie Y Chang; F Joseph Simeone; Martin Torriani; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2017-06-30       Impact factor: 2.199

3.  Single-fraction image-guided extracranial radiosurgery for recurrent and metastatic abdominal and pelvic cancers: short-term local control, metabolic response, and toxicity.

Authors:  Charles L Perkins; Bassel El-Reyes; Edmund Simon; David Kooby; William Torres; John S Kauh; Charles A Staley; Jerome C Landry
Journal:  J Gastrointest Oncol       Date:  2010-09

4.  Osteoblastic response as a healing reaction to chemotherapy mimicking progressive disease in patients with small cell lung cancer.

Authors:  Joerg Stattaus; Steffen Hahn; Thomas Gauler; Wilfried Eberhardt; Stefan P Mueller; Michael Forsting; Susanne C Ladd
Journal:  Eur Radiol       Date:  2008-08-02       Impact factor: 5.315

5.  [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil.

Authors:  S A Suttie; K G M Park; T A D Smith
Journal:  Br J Cancer       Date:  2007-09-11       Impact factor: 7.640

6.  Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.

Authors:  Erwin Woff; Alain Hendlisz; Camilo Garcia; Amelie Deleporte; Thierry Delaunoit; Raphaël Maréchal; Stéphane Holbrechts; Marc Van den Eynde; Gauthier Demolin; Irina Vierasu; Renaud Lhommel; Namur Gauthier; Thomas Guiot; Lieveke Ameye; Patrick Flamen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-12       Impact factor: 9.236
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.